Rivaroxaban vs Vitamin K Antagonist in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease.

ABSTRACT:

Background

Treatment with vitamin K antagonists (VKAs) has been linked to worsening of kidney function in patients with atrial fibrillation (AF).

Objectives

XARENO (Factor XA-inhibition in RENal patients with non-valvular atrial fibrillation Observational registry; NCT02663076) is a prospective observational study comparing adverse kidney outcomes in patients with AF and advanced chronic kidney disease receiving rivaroxaban or VKA.

Methods

Patients with AF and an estimated glomerular filtration rate (eGFR) of 15 to 49 mL/min/1.73 m² were included. Blinded adjudicated outcome analysis evaluated adverse kidney outcomes (a composite of eGFR decline to <15 mL/min/1.73 m², need for chronic kidney replacement therapy, or development of acute kidney inj

SUBMITTER: Kreutz R 

PROVIDER: S-EPMC11198259 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature